Allergan Public Limited Company, Ireland; Watson Merger Sub Inc., Usa; and Pfizer Inc., Usa.
A compact analysis
This page shows the compact analysis of this judgement. The full analysis — procedural history, issue-by-issue holdings with ratio and obiter, advocates, and paragraph-level evidence for every claim — is being added to the record in batches and will appear here when this judgement has been through it.
Summary under Regulation 13 (1)(B) of the Combination Regulations
A summary of the combination, not containing any confidential information, in not more than 500 words, comprising details regarding (a) name of the parties to the combination; (b) the type of the combination; (c) the area of activity of the parties to the combination; and (d) the relevant market(s) to which the combination relates.
A. Name of the parties to the combination
- Allergan plc ( Allergan ); Pfizer Inc. ( Pfizer ); and Watson Merger Sub Inc. ( Merger Sub )
B. Type of the Combination
- This Form II notification is being filed with the Hon’ble Competition Commission of India in accordance with Section 6(2) of the Competition Act, 2002, jointly by Allergan, Pfizer and Merger Sub.
- Pursuant to the proposed transaction, Merger Sub, a newly incorporated wholly owned subsidiary of Allergan will merge with and into Pfizer, a corporation incorporated under the laws of the State of Delaware, U.S.A. As a result, Pfizer will become a wholly owned subsidiary of Allergan and Allergan will be renamed as Pfizer plc.
C. Area of the activity of the parties to the combination
Similar cases
Judgements on the same questions, provisions and authorities, from every court